TSHA
HEALTHCARETaysha Gene Therapies Inc
$6.98+0.04 (+0.58%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving TSHA Today?
No stock-specific AI insight has been generated for TSHA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.06$7.30
$6.98
Fundamentals
Market Cap$2.0B
P/E Ratio—
EPS$-0.38
Dividend Yield—
Dividend / Share—
ROE-1.0%
Profit Margin—
Debt / Equity—
Trading
Volume4.1M
Avg Volume (10D)—
Shares Outstanding287.3M
TSHA News
20 articles- Taysha Gene Therapies, Inc. Q1 2026 Earnings Call SummaryMoby·May 7, 2026
- Taysha Gene Therapies Q1 Earnings Call HighlightsMarketbeat·May 7, 2026
- Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate UpdateYahoo Finance·May 6, 2026
- Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6GlobeNewswire Inc.·Apr 29, 2026
- Has Taysha Gene Therapies (TSHA) Run Too Far After A 259% One Year Surge?Yahoo Finance·Apr 28, 2026
- Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual MeetingYahoo Finance·Apr 27, 2026
- Taysha Gene Therapies (TSHA) Stock Price Surges 343.45% From Year Ago LevelsYahoo Finance·Apr 22, 2026
- This is Why Taysha Gene Therapies, Inc. (TSHA) is one of the Best Healthcare Penny Stocks to BuyYahoo Finance·Apr 14, 2026
- Taysha Gene Therapies (TSHA) Making Progress on Crucial Rett Syndrome TreatmentYahoo Finance·Apr 6, 2026
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc.·Apr 3, 2026
- Structure Therapeutics Slides 28% This Year as $6 Million Stake EmergesMotley Fool·Mar 22, 2026
- How FDA Breakthrough Status For TSHA-102 At Taysha Gene Therapies (TSHA) Has Changed Its Investment StoryYahoo Finance·Mar 21, 2026
- Taysha Gene Therapies Inc (TSHA) Q4 2025 Earnings Call Highlights: Strong Cash Position and ...Yahoo Finance·Mar 19, 2026
- Taysha Gene Therapies, Inc. Q4 2025 Earnings Call SummaryMoby·Mar 19, 2026
- Taysha Gene Therapies Q4 Earnings Call HighlightsMarketbeat·Mar 19, 2026
- Taysha (TSHA) Q4 2025 Earnings Call TranscriptMotley Fool·Mar 19, 2026
- Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Mar 19, 2026
- Taysha Gene Therapies Inc (TSHA) Q4 2025 Earnings Report Preview: What To ExpectYahoo Finance·Mar 18, 2026
- Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19Yahoo Finance·Mar 12, 2026
- Did Rett Trial Milestones Just Shift Taysha Gene Therapies' (TSHA) Gene Therapy Approval Path Narrative?Yahoo Finance·Feb 4, 2026
All 20 articles loaded
Price Data
Open$6.61
Previous Close$6.94
Day High$7.30
Day Low$6.50
52 Week High$7.30
52 Week Low$2.06
52-Week Range
$2.06$7.30
$6.98
Fundamentals
Market Cap$2.0B
P/E Ratio—
EPS$-0.38
Dividend Yield—
Dividend / Share—
ROE-1.0%
Profit Margin—
Debt / Equity—
Trading
Volume4.1M
Avg Volume (10D)—
Shares Outstanding287.3M
About Taysha Gene Therapies Inc
Taysha Gene Therapies, Inc., a gene therapy company, focuses on the development and commercialization of adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company is headquartered in Dallas, Texas.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—